And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest. Once again, we are taking in another installment in our “Let’s-see-them-before-they-die” concert series. We also plan to see the Pharmalot ancestors and, otherwise, catch up on some reading. And what about you? This is a fine time to enjoy the great outdoors. Perhaps, this is an opportunity to tidy up around the castle. Or reach out to someone special. Remember, life is short. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
Insys Therapeutics (INSY), whose former executive team was arrested for allegedly bribing doctors to prescribe its opioid painkiller, has set aside $150 million to cover a settlement amid ongoing talks with the U.S. Department of Justice, according to a filing with the Securities and Exchange Commission. This does not cover possible deals with various states or other organizations, but suggests a deal with DoJ “may be close at hand,” writes Jefferies analyst David Steinberg.
AmerisourceBergen (ABC) expects stubbornly low generic drug prices, which have plagued drug makers and wholesalers, not to deteriorate further next year, Reuters writes. The wholesaler expects generic drug prices to fall 7 percent to 9 percent in the current fiscal year that ends next September. “It’s still high, but it’s not getting worse, which we think is a positive,” Steven Collis, ABC chief executive, tells the news service.
About the Author Reprints
Given that the “EpiPen Jr” is so new a product, was this just completeness – “the agency received a total of 228 reports of EpiPen or EpiPen Jr. failures during the same time period” – or is the”Jr” significant nexus of failure? The referenced piece gives no clue – and the FDA may not have either but ‘it’s a thought.’